P1.03D.01 Efficacy and Biomarker Analysis of Neoadjuvant ...

According to postoperative pathological evaluation, 54 (65.1%) patients achieved major pathological response. For MPR patients, both the MFR score and CAFF ...

We demonstrated the efficacy of neoadjuvant toripalimab combined with chemotherapy and the predictive value of MFR and CAFF score in neoadjuvant ...

P1.03D.01 Efficacy and Biomarker Analysis of Neoadjuvant ...

P1.03D.01 Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC) · Download ...

IASLC-WCLC 2024: Efficacy and Biomarker Analysis of ...

P1.03D.01 - Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC) ...

E. Zhang's research works - ResearchGate

E. Zhang's 1 research works with 0 citations, including: P1.03D.01 Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in ...

PROGRAM BOOK - WCLC 2024 - IASLC

... 01 / Conference Overview. Page 9. WCLC 2024 Program Book. 9. IASLC WCLC 2024 ... P1.12A.08: The Mechanism Study on a Novel. CD3-EGFR Bispecific Antibody ...

Clinical efficacy and biomarker analysis of neoadjuvant ... - PubMed

Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers 1 ...

an experimental single-arm phase II clinical trial pilot study - PubMed

A commentary on 'Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: an ...

2024 World Conference on Lung Cancer (WCLC) - Posters

P1.08C.01 Targeted Therapy or Chemotherapy as Neoadjuvant ... P1.08D.01 The Efficacy of Durvalumab after ... P1.13A.08 Biomarker Analysis of Camrelizumab Plus ...

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK ...

When BR19 was initiated, it was unknown that activating mutations of EGFR were biomarkers of efficacy for EGFR-TKI and patients were unselected for the EGFR+ ...

君实生物特瑞普利单抗多项研究成果入选2024 WCLC医药新闻 ...

... P1.03D.01 特瑞普利单抗联合化疗新辅助治疗可切除IIB-IIIB期非小细胞肺癌(NSCLC)的疗效和生物标志物分析. Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab ...

Phase II study of biomarker-guided neoadjuvant treatment strategy ...

The BIM deletion polymorphism had no correlation with TKI efficacy (Additional file 1). Immunohistochemistry (IHC) was conducted to detect ...

Exploring biological heterogeneity and its consequences at tissue ...

2.5.1 Fitting the mathematical model to patient data by a regression analysis identifies biologically realistic parameter values ………………………………….……….38. 2.5.2 ...

Evaluating the predictive value of biomarkers for efficacy outcomes ...

factor receptor 2 (HER2)-positive breast cancer in the neoadjuvant setting. We analyzed ... An exploratory analysis of biomarkers to determine ...

2024 WCLC | 創新風暴襲來！一文解鎖免疫治療的花樣玩法- 天天看點

摘要号：P1.03D.01. 英文标題：Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung ...